Katie Ellias

Katie Ellias serves as a Board Member at SAb Biotherapeutics and the WHARTON HEALTH CARE MANAGEMENT ALUMNI ASSOCIATION. Additionally, Katie is the Managing Director of the T1D Fund, a venture philanthropy initiative focused on type 1 diabetes solutions, and holds board observer roles at several organizations, including Seraxis, i2o Therapeutics, and Biolinq. Previous board positions include membership at VERALOX Therapeutics and Capillary Biomedical. Katie’s academic background includes an MBA in Health Care Marketing from The Wharton School and a BA in Political Science and International Relations from Yale University.